Article
Immunology
Elke Jordan, Golam Kabir, Stephanie Schultz, Guenter Silbernagl, Darja Schmidt, Victoria A. Jenkins, Heinz Weidenthaler, Daria Stroukova, Barbara K. Martin, Laurence De Moerlooze
Summary: MVA-BN-RSV vaccination reduces viral load and symptom scores, decreases the number of confirmed infections, and induces humoral and cellular immune responses against respiratory syncytial virus (RSV).
JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Virology
Li-Nan Wang, Xiang-Lei Peng, Min Xu, Yuan-Bo Zheng, Yue-Ying Jiao, Jie-Mei Yu, Yuan-Hui Fu, Yan-Peng Zheng, Wu-Yang Zhu, Zhong-Jun Dong, Jin-Sheng He
Summary: This study successfully developed three recombinant RSV strains as potential vaccines against RSV infection, demonstrating their attenuated effects and antigen stability in mice. Through a series of experiments, the researchers proved that combining attenuation mutations and SH gene deletion improved the efficacy and stability of the vaccines.
Article
Fisheries
M. Makesh, N. Venkata Satyanarayana, K. Muddukrishnaiah, Sujeet Kumar, G. Thiagarajan, Ashok Kumar Jangam, R. Subburaj, M. Kailasam, K. K. Vijayan
Summary: The red-spotted grouper nervous necrosis virus (RGNNV) is the most prevalent genotype among fishes in tropical and temperate regions. Inactivated and recombinant VNN vaccines produced significant immune responses in Asian seabass fingerlings and broodstock, and also demonstrated efficacy under field conditions. The vaccine can be used to vaccinate broodstock to reduce loss due to VNN in early larval stages.
Article
Multidisciplinary Sciences
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, Alexandra Kupke, Georgia Kalodimou, Leonard Limpinsel, Nisreen M. A. Okba, Berislav Bosnjak, Inga Sandrock, Ivan Odak, Sandro Halwe, Lucie Sauerhering, Katrin Brosinski, Liangliang Nan, Elke Duell, Sylvia Jany, Astrid Freudenstein, Joerg Schmidt, Anke Werner, Michelle Gellhorn Serra, Michael Kluever, Wolfgang Guggemos, Michael Seilmaier, Clemens-Martin Wendtner, Reinhold Foerster, Bart L. Haahmans, Stephan Becker, Gerd Sutter, Asisa Volz
Summary: The SARS-CoV-2 virus has caused the COVID-19 pandemic, and a recombinant MVA expressing the SARS-CoV-2 spike protein shows promise as a candidate for developing a COVID-19 vaccine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Immunology
Rama Raghunandan, Deborah Higgins, Nancy Hosken
Summary: RSV is a major cause of respiratory illness in children and infants worldwide, with no licensed vaccine available. Multiple RSV vaccine candidates are in clinical development, with a focus on inducing robust virus neutralizing immune responses through nAb-mediated interventions. Standardizing RSV neutralization assays is crucial for assessing nAb responses accurately and for comparing the immunogenicity of different vaccine candidates.
Article
Immunology
Vadim Ivanov, Antonius G. P. Oomens, James F. Papin, Rachel Staats, Darlene N. Reuter, Zhongxin Yu, Pedro A. Piedra, Robert C. Wellliver
Summary: RSV is a major viral respiratory pathogen for infants and children, with no licensed vaccine available. A vaccine has been developed using a human RSV strain with the M protein gene deleted, preventing viral replication. Vaccination led to reduced illness signs and viral replication in infected animals, supporting further development for human use.
Review
Microbiology
Federica Attaianese, Sara Guiducci, Sandra Trapani, Federica Barbati, Lorenzo Lodi, Giuseppe Indolfi, Chiara Azzari, Silvia Ricci
Summary: This review comprehensively summarizes the immune response to human respiratory syncytial virus (hRSV) infection, including innate and adaptive immune components, recognition of the virus, inflammatory response, natural killer cells, antigen presentation, T cell response, and antibody production. Understanding the complex immune response to hRSV infection is crucial for developing effective interventions against this significant respiratory pathogen.
Article
Immunology
Tino F. Schwarz, Casey Johnson, Christine Grigat, Dan Apter, Peter Csonka, Niklas Lindblad, Thi Lien-Anh Nguyen, Feng F. Gao, Hui Qian, Antonella N. Tullio, Ilse Dieussaert, Marta Picciolato, Ouzama Henry
Summary: This first-in-human, placebo-controlled study showed that the unadjuvanted RSVPreF3 vaccine, at doses of 30, 60, or 120 μg, was well tolerated and immunogenic. Dose levels of 60 and 120 μg exhibited significantly higher immunogenicity compared to the 30 μg dose, leading to further investigation in pregnant women.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Javier Diez-Domingo, Xavier Saez-Llorens, Miguel A. Rodriguez-Weber, Cristina Epalza, Archana Chatterjee, Cheng-Hsun Chiu, Chien-Yu Lin, Andrea A. Berry, Federico Martinon-Torres, Fernando Baquero-Artigao, Joanne M. Langley, Jose T. Ramos Amador, Joseph B. Domachowske, Li-Min Huang, Nan-Chang Chiu, Susanna Esposito, Philippe Moris, Thi Lien-Anh Nguyen, Vanja Nikic, Wayne Woo, Yingjun Zhou, Ilse Dieussaert, Amanda Leach, Antonio Gonzalez Lopez, Nicolas Vanhoutte
Summary: This study tested a new candidate RSV vaccine in toddlers who had a previous RSV infection. The vaccine was effective in preventing RSV-related illnesses and triggered an antibody response that could neutralize the virus. No vaccine-related serious adverse events or RSV-related hospitalizations were reported during the study.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, Kevin Tetteh, Mattu Tehtor Kroma, Godfrey Tuda Otieno, Bolarinde Joseph Lawal, Seyi Soremekun, Philip Ayieko, Auguste Gaddah, Abu Bakarr Kamara, Frank Baiden, Muhammed Olanrewaju Afolabi, Daniel Tindanbil, Kwabena Owusu-Kyei, David Ishola, Gibrilla Fadlu Deen, Babajide Keshinro, Yusupha Njie, Mohamed Samai, Brett Lowe, Cynthia Robinson, Bailah Leigh, Chris Drakeley, Brian Greenwood, Deborah Watson-Jones, Junki Maruyama
Summary: We evaluated the immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in individuals with previous exposure to malaria and those who experienced clinical malaria after vaccination. We found that there was no difference in antibody responses to the Ebola virus glycoprotein between different categories of previous malaria exposure. We also found that the vaccine regimen was effective in individuals who experienced clinical malaria after vaccination.
Article
Multidisciplinary Sciences
Hai Li, Hu Ren, Yan Zhang, Lei Cao, Wenbo Xu
Summary: In this study, intranasal immunization with the recombinant protein CTA1-DD-RBF in mice effectively stimulated specific immune responses and generated protective immunity without inducing lung immunopathology. Compared to other proteins, CTA1-DD-RBF exhibited superior immune protection.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Luca M. Zaeck, Mart M. Lamers, Babs E. Verstrepen, Theo M. Bestebroer, Martin E. van Royen, Hannelore Gotz, Marc C. Shamier, Leanne P. M. van Leeuwen, Katharina S. Schmitz, Kimberley Alblas, Suzanne van Efferen, Susanne Bogers, Sandra Scherbeijn, Guus F. Rimmelzwaan, Eric C. M. van Gorp, Marion P. G. Koopmans, Bart L. Haagmans, Corine H. GeurtsvanKessel, Rory D. de Vries
Summary: In July 2022, the monkeypox outbreak was declared an international public health emergency. Historic smallpox vaccination and monkeypox virus infection can generate MPXV-neutralizing antibodies, but vaccination with MVA-BN results in lower levels of these antibodies. Further studies are needed to assess the efficacy of the MVA-BN vaccine in at-risk populations.
Article
Biochemistry & Molecular Biology
Onur Kaynarcalidan, Sara Moreno Mascaraque, Ingo Drexler
Summary: Various strains of vaccinia virus were used to eradicate smallpox virus globally. Modified vaccinia virus Ankara (MVA) is a popular vaccine strain with advantages for developing recombinant vaccine candidates. By manipulating certain genes, researchers aim to improve the immunogenicity and safety of MVA-based viral vector vaccines.
Article
Immunology
Kathrin Endt, Yvonne Wollmann, Jana Haug, Constanze Bernig, Markus Feigl, Alexander Heiseke, Markus Kalla, Hubertus Hochrein, Mark Suter, Paul Chaplin, Ariane Volkmann
Summary: Respiratory syncytial virus (RSV) is a respiratory disease that poses a potential fatality risk to infants and elderly individuals. Despite previous failed attempts, researchers have developed an RSV vaccine using recombinant Modified Vaccinia Virus Ankara-BN (MVA-RSV), which has shown promising results in clinical trials. This study demonstrates that the MVA-RSV vaccine provides optimal protection against RSV infection by activating multiple components of the adaptive immune system, including CD4 and CD8 T cells and antibodies such as IgA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
James Baber, Mark Arya, Yuben Moodley, Anna Jaques, Qin Jiang, Kena A. Swanson, David Cooper, Mohan S. Maddur, Jakob Loschko, Alejandra Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Beate Schmoele-Thoma
Summary: The stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate was well tolerated and elicited strong and persistent serum neutralizing responses in adults aged 65-85, with or without adjuvant. Adjuvanted formulations did not show additional enhancement of immune responses.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Edgar Turner Overton, Steven J. Lawrence, Eva Wagner, Katrin Nopora, Siegfried Roesch, Philip Young, Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P. Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin
Article
Medicine, General & Internal
Phillip R. Pittman, Matthew Hahn, HeeChoon S. Lee, Craig Koca, Nathaly Samy, Darja Schmidt, Joachim Hornung, Heinz Weidenthaler, Christopher R. Heery, Thomas P. H. Meyer, Guenter Silbernagl, Jane Maclennan, Paul Chaplin
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Article
Immunology
Nathaly Samy, Daniela Reichhardt, Darja Schmidt, Liddy M. Chen, Guenter Silbernagl, Sanja Vidojkovic, Thomas P. H. Meyer, Elke Jordan, Tatiana Adams, Heinz Weidenthaler, Dania Stroukova, Sonja De Carli, Paul Chaplin
Article
Immunology
Edgar Turner Overton, Steven J. Lawrence, Jack T. Stapleton, Heinz Weidenthaler, Darja Schmidt, Brigitte Koenen, Guenter Silbernagl, Katrin Nopora, Paul Chaplin
Review
Immunology
Ariane Volkmann, Anna-Lise Williamson, Heinz Weidenthaler, Thomas P. H. Meyer, James S. Robertson, Jean-Louis Excler, Richard C. Condit, Eric Evans, Emily R. Smith, Denny Kim, Robert T. Chen
Summary: The Brighton Collaboration Viral Vector Vaccines Safety Working Group was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines, with a focus on the Modified Vaccinia Ankara (MVA) vector system. The MVA-BN-Filo vaccine, based on a highly attenuated poxviral vector, has been approved in the European Union and used as part of a heterologous Ebola vaccination regimen. Studies have shown a safety profile consistent with other licensed vaccines, making it a promising tool in preventing diseases from high-consequence human pathogens.
Meeting Abstract
Infectious Diseases
E. T. Overton, S. Lawrence, J. Stapleton, H. Weidenthaler, D. Schmidt, K. Nopora, T. Meyer, J. Maclennan, B. Koenen, G. Silbernagl, A. Volkmann, P. Chaplin
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2020)
Article
Immunology
Heiko Ilchmann, Nathaly Samy, Daniela Reichhardt, Darja Schmidt, Jacqueline D. Powell, Thomas P. H. Meyer, Guenter Silbernagl, Rick Nichols, Heinz Weidenthaler, Laurence De Moerlooze, Liddy Chen, Paul Chaplin
Summary: One or 2 primary MVA BN vaccinations induced similar durable B-cell memory responses as a booster administered 2 years after primary vaccination showed rapid and robust antibody response. No safety concerns were identified following the booster.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Edgar Turner Overton, Darja Schmidt, Sanja Vidojkovic, Erika Menius, Katrin Nopora, Jane Maclennan, Heinz Weidenthaler
Summary: Vaccination is crucial for preventing orthopox virus-induced diseases, and the storage and stockpiling of vaccines are of significant public health importance. A phase 3 trial evaluated the immunogenicity and safety of freeze-dried formulation of the smallpox vaccine. The results showed that the freeze-dried formulation had consistent immunogenicity and safety.
Letter
Medicine, General & Internal
Phillip R. Pittman, Heinz Weidenthaler, Paul Chaplin
NEW ENGLAND JOURNAL OF MEDICINE
(2020)